Studying blood changes in people with obesity and liver disease
Follows adults with severe obesity and liver disease after a diet or bariatric surgery.
Plain-language title generated from the registry record
Registry title: Changes in the Lipidomic, Immunological and miRNA Profile in Patients Undergoing a Dietary Program or Bariatric Surgery
Key facts
- Where
- Castellana Grotte, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who also have a liver or bile duct disease. They follow a diet program or have weight-loss surgery.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Obesity with BMI above 30 kg/m2 and a liver or bile duct disease found by Fibroscan
Main reasons for not taking part
- People who are not obese
- People without a liver or bile duct disease
Read by machine on 12 November 2026.
Where in Italy
- IRCCS "Saverio de Bellis"Castellana Grotte, ItalyContact: Rossella Donghia, BiologystTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Trial code
- NCT06372015
- Record updated
- 4 April 2025
- Original description
Obesity is a chronic disease characterized phenotypically by an increase in body weight (BMI>30 kg/m2) and by a series of associated pathologies, such as hypertension, diabetes, hepatic steatosis.Read full original descriptionShow less
Changes in the Lipidomic, Immunological and Circulating microRNA Profile in Patients With Hepatobiliary Pathology, Suffering From Morbid Obesity Undergoing a Dietary Program or Bariatric Surgery
Obesity is a chronic disease characterized phenotypically by an increase in body weight (BMI>30 kg/m2) and by a series of associated pathologies, such as hypertension, diabetes, hepatic steatosis.
The association of these pathologies compromises the patient's survival and quality of life. The multifactorial origin of obesity makes its etiopathology difficult to manage. It is often possible to follow only one therapeutic strategy, especially after the so-called standard treatments, such as dietary intervention and physical activity, have not brought benefit to the patient. In these cases, an appropriate treatment for the patient to enjoy significant weight loss is bariatric surgery.
Bariatric surgery refers to all those interventions aimed at reducing weight in those suffering from obesity, and treating the diseases associated with it.
Among the different types of bariatric surgery, the techniques most used in common clinical practice are intragastric balloons, gastric by pass (RYGB) and sleeve gastrectomy.
The choice of the surgeon, assisted by the multidisciplinary team, is binding in the choice of the type of operation to which the patient will be subjected.
Inclusion: Obese patients (BMI >30kg/m2) suffering from hepato-biliary pathology diagnosed by Fibroscan; Adult patients (>18 years).
Exclusion: Patients who are not obese or not affected by hepato-biliary pathology.